Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept in Refractory Rheumatoid Arthritis
NCT07796516Phase 2Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Sep 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
A Phase 2 trial of telitacicept in rheumatoid arthritis (RA), sponsored by Peking University People's Hospital. Started Sep 2026; status: recruiting.
02
Drugs
telitacicept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT07796516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07796516.